字号·· | 护眼
福克斯新闻网

热门减肥药或可防止糖尿病前期发展为糖尿病Popular weight-loss drugs may prevent prediabetes from turning into diabetes

点「原文对照」整页切到原文,或双击某段只看那段的原文。

服用基于GLP-1的药物的糖尿病前期和肥胖成年人,患2型糖尿病的风险比服用二甲双胍的人低31%,死亡风险低41%。(iStock)Adults with prediabetes and obesity who took GLP-1-based medications had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death compared with those taking metformin. (iStock)

患有糖尿病前期和肥胖的成年人,若使用基于GLP-1的药物,与服用二甲双胍的人相比,患2型糖尿病的风险降低31%,死亡风险降低41%。

Adults with prediabetes and obesity who took GLP-1-based medications had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death compared with those taking metformin.

二甲双胍是一种口服药物,主要用于治疗2型糖尿病,被广泛视为一线治疗方案,需结合生活方式干预。有时也会为糖尿病前期患者开具该药,以帮助预防或延缓病情进展。

Metformin is an oral medication used primarily to treat type 2 diabetes, widely considered the first-line treatment, combined with lifestyle modifications. It is also sometimes prescribed to people with prediabetes to help prevent or delay progression.

这些发现来自一项大型观察性研究,将于本周末在美国心脏协会2026年科学年会上公布,会议地点在芝加哥。研究结果尚未经过完整的同行评审过程。

The findings, which come from a large observational study, are set to be presented at the American Heart Association’s Scientific Sessions 2026 this weekend in Chicago. They have not yet undergone the full peer review process.

该研究涉及256,492名糖尿病前期和肥胖成年人的健康记录,平均年龄为52岁。

The study involved health records for 256,492 adults with prediabetes and obesity, averaging 52 years of age.

该群体中约一半人使用GLP-1(胰高血糖素样肽-1受体激动剂)药物——包括司美格鲁肽、替尔泊肽、利拉鲁肽和度拉鲁肽——另一半人使用二甲双胍。

Approximately half of the group received GLP-1 (glucagon-like peptide-1 receptor agonists) medications – including semaglutide, tirzepatide, liraglutide and dulaglutide – and half received metformin.

根据三年随访数据,除了糖尿病和全因死亡率风险降低外,基于GLP-1的药物还与中风减少20%、心脏病发作减少15%、心力衰竭病例减少25%相关。

Based on a three-year follow-up, in addition to the lower risk of diabetes and all-cause mortality, GLP-1–based medications were associated with 20% fewer strokes, 15% fewer heart attacks and 25% fewer cases of heart failure.

“任何原因导致的死亡风险降低41%让我最为惊讶,”研究作者、亚利桑那州斯科茨代尔梅奥诊所心血管医学系研究员维尼修斯·德·索萨·巴尔宗·塞拉博士(Vinicius de Sousa Barzon Serra, M.D.)告诉福克斯新闻数字版。

"The 41% lower risk of death from any cause surprised me most," study author Vinicius de Sousa Barzon Serra, M.D., a research fellow in the department of cardiovascular medicine at the Mayo Clinic in Scottsdale, Arizona, told Fox News Digital.

“我原本预期GLP-1药物在血糖和糖尿病风险方面会优于二甲双胍,因为它们能带来更多的体重减轻。我也注意到,这种益处出现在多种结局中,包括心脏病发作、中风、心力衰竭和心房颤动。”

"I expected GLP-1 medications to do better than metformin on blood sugar and diabetes risk, because they lead to much more weight loss. I was also struck that the benefit appeared across many outcomes, including heart attack, stroke, heart failure and atrial fibrillation." Nearly 40% of U.S. adults have prediabetes, according to statistics from the AHA. That condition is marked by blood sugar levels that are above normal but not yet elevated enough for a diabetes diagnosis.

根据美国心脏协会的统计数据,近40%的美国成年人患有糖尿病前期。该病症的特征是血糖水平高于正常,但尚未达到糖尿病诊断标准。多达10%的糖尿病前期患者每年会发展为2型糖尿病。

As many as 10% of those with prediabetes will go on to develop type 2 diabetes each year.

“此前关于这些药物的大多数研究都集中在已经患有糖尿病的人群身上,”塞拉指出。“我们的研究表明,糖尿病前期阶段可能是考虑使用这些药物的重要时期,而不是等到他们发展为2型糖尿病。”该研究也存在一些局限性。虽然研究发现GLP-1药物与更好的健康结局之间存在关联,但并不能证明药物是原因。

"Most earlier research on these medications focused on people who already had diabetes," Serra noted. "Our study suggests the prediabetes stage may be an important time to consider them, rather than waiting until they develop type 2 diabetes." The study did have some limitations. While it found a link between GLP-1 medications and better health outcomes, it does not prove that the drugs were responsible.

据美国心脏协会统计,近40%的美国成年人患有糖尿病前期。该病症表现为血糖水平高于正常,但尚未达到糖尿病诊断标准。(iStock)Nearly 40% of U.S. adults have prediabetes, according to statistics from the AHA. That condition is marked by blood sugar levels that are above normal but not yet elevated enough for a diabetes diagnosis. (iStock)

塞拉指出,这些发现属于初步结果,尚未在经过同行评审的期刊上发表。

The findings are preliminary until published in a peer-reviewed journal, Serra noted.

“我们按年龄、健康状况和其他特征对患者进行了匹配,以使各组可比……即便如此,各组之间可能仍存在其他差异,”他说。“我们还将GLP-1药物归为一类,因此无法判断单个药物是否存在差异。”该研究依赖于患者的电子健康记录,这些记录可能包含缺失或错误的信息。研究人员还指出,研究中未测量的因素,例如药物剂量和依从性,也可能影响了结果。

"We matched patients by age, health conditions and other characteristics to make the groups comparable … even so, other differences between the groups may remain," he said. "We also grouped the GLP-1 medications together, so we could not tell whether individual drugs differ." The study relied on patients' electronic health records, which may have contained missing or incorrect information. It is also possible that factors not measured in the study, such as medication dosage and compliance, could have influenced the results, the researchers noted.

二甲双胍是一种口服药物,主要用于治疗2型糖尿病,被广泛视为一线治疗方案,需配合生活方式干预。有时也会为糖尿病前期患者开具该药,以帮助预防或延缓病情进展。(Scott Olson/Getty Images)Metformin is an oral medication used primarily to treat type 2 diabetes, widely considered the first-line treatment, combined with lifestyle modifications. It is also sometimes prescribed to people with prediabetes to help prevent or delay progression. (Scott Olson/Getty Images)

塞拉建议,患有糖尿病前期和肥胖的人应该与医生讨论所有选择,不应自行停药或更改任何药物。

People with prediabetes and obesity should talk with their doctor about all their options and should not stop or change any medication on their own, Serra advised.

“二甲双胍是一种安全、廉价且有着长期使用记录的选择,健康饮食、规律体育活动和体重管理等生活方式改变仍然是治疗的基础,”他向福克斯新闻数字版强调。

"Metformin is a safe, inexpensive option with a long track record, and lifestyle changes such as healthy eating, regular physical activity and weight management remain the foundation of treatment," he emphasized to Fox News Digital.

“对于某些患者来说,根据其整体健康状况、其他疾病、费用和可及性,GLP-1药物可能值得讨论。决定应与医生共同做出。”

"For some patients, a GLP-1 medication may be worth discussing, depending on their overall health, other medical conditions, cost and access. The decision should be made together with their doctor."

阅读媒体原文 ↗